At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 84 enrolled
Drug / intervention
Taladegibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating Taladegib for Advanced Cancer. Completed, enrolled 84 participants across 12 sites.
Detailed Summary
The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedOct 2010
Primary CompletionJan 2015
Study CompletionOct 2017
TodayJul 2026
First PostedOct 22, 2010
Enrollment StartSep 1, 2010
Primary CompletionJan 1, 2015
Study CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.7 years ago
Interventions
Taladegibdrug
Administered IV